Date Name Title Filing Type Shares Traded Price Total Held
Dec 15, 2016
Director, President Regeneron Laboratori
Director, President Regeneron Laboratori Form 4 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 195,079 -- --
Dec 18, 2006
Director, EVP, CSO, & Pres Regn Res Labs
Director, EVP, CSO, & Pres Regn Res Labs Form 4 Grant, award or other acquisition pursuant to Rule 16b-3(d) 195,079 -- 195,079
Dec 13, 2017
Director, President & CSO
Director, President & CSO Form 4 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 195,438 $21.92 786,786
Dec 13, 2017
Director, President & CSO
Director, President & CSO Form 4 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 195,438 -- --
Dec 17, 2007
Director, EVP, CSO, & Pres Regn Res Labs
Director, EVP, CSO, & Pres Regn Res Labs Form 4 Grant, award or other acquisition pursuant to Rule 16b-3(d) 195,438 -- 195,438
Nov 30, 2011
Director, EVP CSO President Regeneron Re
Director, EVP CSO President Regeneron Re Form 4 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 196,430 $28.01 1,066,135
Nov 30, 2011
Director, EVP CSO President Regeneron Re
Director, EVP CSO President Regeneron Re Form 4 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 196,430 -- --
Dec 13, 2013
Director, Pres Regeneron Labs
Director, Pres Regeneron Labs Form 4 Grant, award or other acquisition pursuant to Rule 16b-3(d) 203,204 -- 203,204
Jun 24, 2021
Director, President and Chief Scientific
Director, President and Chief Scientific Form 4 Bona fide gift 211,585 -- 213,693
Jun 24, 2021
Director, President and Chief Scientific
Director, President and Chief Scientific Form 4 Bona fide gift 211,585 -- --

* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.